The evolving treatment landscape in immune thrombocytopenia
The evolving treatment landscape in immune thrombocytopenia
Highlights from APCCC 2026
ASCO 2026: Updates in bladder cancer
ASCO 2026: Updates in renal cancer
Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma
Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure
DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation
Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia